Resonance Health Limited (RHT.AX)’s FerriScan® R2-MRI Receives FDA Marketing Authorization as the First Imaging Companion Diagnostic Device for Exjade® in Patients With Non-Transfusion-Dependent Thalassemia (NTDT)
1/31/2013 10:32:36 AM
More...
|
Resonance Health Limited (RHT.AX) Receives FDA Approval for MRI-Q Cardiac Iron T2* Test
8/16/2011 6:43:01 AM
More...
|
Resonance Health Limited (RHT.AX) Release: FDA Approves FerriScan(TM) Non-invasive Test For Iron Overload Disease
10/19/2005 5:12:34 PM
More...
|